Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07780669

A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-1)

Conditions: Pulmonary Disease, Chronic Obstructive

Sex: All

Ages: 40 Years – 80 Years

Healthy volunteers: No

Phase: PHASE3

Enrollment: 624

Sponsor: GlaxoSmithKline

Location: GSK Investigational Site Doral Florida

Summary

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Eligibility Criteria

Inclusion Criteria: * Male or eligible female participants * Participants with \>=40 to less than or equal to (\

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07780669). StuddyBuddy aggregates publicly available trial information.